Eisai Inc.
900 Davis Drive
P.O. Box 14505
Research Triangle Park
North Carolina
27709
United States
Tel: 919-941-6920
Fax: 919-941-6931
Website: http://www.eisai.com/
About Eisai Inc.
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
186 articles about Eisai Inc.
-
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
-
Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the...
-
The FDA accepted Merck & Co.’s supplemental Biologics License Application and granted Priority Review for Keytruda in advanced cervical cancer.
-
H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research in Hepatocellular Carcinoma Published in December Issue of Cancer Research
12/15/2017
The data were recently presented at the International Liver Cancer Association annual meeting held in Seoul, Republic of Korea.
-
H3 Biomedicine Advances RNA Splicing Platform Through Collaborations With Key Academic Centers
12/11/2017
H3 Biomedicine announced that data from the company’s academic collaborations in RNA splicing biology will be presented over the next three days at the 2017 American Society of Hematology (ASH) meeting in Atlanta, GA.
-
Eisai and Purdue Pharma L.P. Presented Lemborexant Data From Research Studies at ACNP Annual Meeting
12/7/2017
The Asakura et al. poster presentation reported a non-clinical study demonstrating differences in lemborexant abuse liability when compared to a currently marketed insomnia treatment, suvorexant.
-
H3 Biomedicine Presents Preclinical Data on Novel ERα Antagonist at San Antonio Breast Cancer Symposium
12/7/2017
The poster presented at SABCS demonstrated that H3B-6545 has a unique mode of ERα antagonism and exhibits superior preclinical anti-tumor activity to fulvestrant in the MCF-7 xenograft model with once daily oral dosing, achieving maximal antitumor activity at doses >10x below the maximum tolerated dose in mice.
-
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
11/27/2017
Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.
-
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany From December
11/20/2017
Eisai has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds have agreed on a reimbursement price for Eisai's antiepileptic drug Fycompa.
-
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
11/20/2017
Eisai has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 IT Awards held by the Japan Institute of Information Technology.
-
Biogen and Eisai Expand Alzheimer's R&D Collaboration
10/23/2017
Under the deal, Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta antibody for patients with Alzheimer’s disease.
-
Grupo Biotoscana And Eisai Inc. Sign Exclusive Licensing Agreement For Four Novel Oncology And Neurology Products In Latin America
10/3/2017
-
Eisai Inc. And Grupo Biotoscana Sign Exclusive Licensing Agreement For The Commercialization Of Eisai's Oncology And Neurology Products Throughout Latin America
10/3/2017
-
FDA Accepts Supplemental New Drug Application For Eisai Inc.'s Lenvatinib For The Treatment Of Liver Cancer
9/27/2017
-
Michael Amoroso Appointed Senior Vice President, Americas Commercial, Oncology Business Group At Eisai Inc.
9/25/2017
-
Eisai Inc. To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress
9/1/2017
-
Eisai Inc. Release: Lenvatinib Significantly Improved Overall Survival In Older Patients With Locally Recurrent Or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According To Results Of Subanalysis Of Phase III SELECT
8/28/2017
-
FDA Approves Eisai Inc.'s FYCOMPA (Perampanel) For Use As Monotherapy For The Treatment Of Partial-Onset Seizures
7/27/2017
-
Eisai Inc. Submits Supplemental New Drug Application To FDA For Lenvatinib In First-Line Hepatocellular Carcinoma
7/25/2017
-
Eisai Inc. Announces Lorcaserin HCl CAMELLIA-TIMI 61 Study Will Continue As Planned Based On Interim Safety Analysis By Independent Data Monitoring Committee (DMC)
6/21/2017